Abstract
Immunomodulatory drugs (IMiDs) currently used in the treatment of multiple myeloma, are thalidomide, lenalidomide and pomalidomide. One of the most common side effects of thalidomide is neurotoxicity, predominantly in the form of peripheral neuropathy. We report 6 cases of significant central neurotoxicity associated with IMiD therapy. Treatment with thalidomide (1 patient), lenalidomide (4 patients), and pomalidomide (1 patient) was associated with various clinical manifestations of central neurotoxicity, including reversible coma, amnesia, expressive aphasia, and dysarthria. Central neurotoxicity should be recognized as an important side effect of IMiD therapy.
Highlights
Abstract the duration of the treatment and to the of data and final approval of the manuscript. cumulative drug dosage.[8,9] Central nervous system (CNS) toxicity is usually mild, and Conflict of interests: the authors declare no Immunomodulatory drugs (IMiDs) current- mainly consists of somnolence
Central neurotoxicity l should be recognized as an important side ia effect of IMiD therapy. erc Introduction m Immunomodulatory drugs (IMiDs) are a m class of antineoplastic compounds which o include thalidomide and its derivatives lenalidomide and pomalidomide
The most common form is peripheral neuropathy, which manifests with hypoesthesia, paresthesia, and hyperesthesia, often in a stocking and glove distribution
Summary
Abstract the duration of the treatment and to the of data and final approval of the manuscript. cumulative drug dosage.[8,9] Central nervous system (CNS) toxicity is usually mild, and Conflict of interests: the authors declare no Immunomodulatory drugs (IMiDs) current- mainly consists of somnolence. Cumulative drug dosage.[8,9] Central nervous system (CNS) toxicity is usually mild, and Conflict of interests: the authors declare no Immunomodulatory drugs (IMiDs) current- mainly consists of somnolence. Treatment o with thalidomide (1 patient), lenalidomide (4 patients), and pomalidomide (1 patient) was e associated with various clinical manifestas tions of central neurotoxicity, including reversible coma, amnesia, expressive aphau sia, and dysarthria. Erc Introduction m Immunomodulatory drugs (IMiDs) are a m class of antineoplastic compounds which o include thalidomide and its derivatives lenalidomide and pomalidomide. N The use of thalidomide resurfaced when it was high doses (400 mg/day and above), patients can experience severe lethargy.[10] For lenalidomide and pomalidomide, CNS toxicity (with exception of confusion) has not been established as a known adverse effect. We report 6 MM patients who developed significant CNS toxicity during treatment with IMiD agents
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
